Biogen Announces Board Chair Transition

Core Viewpoint - Biogen Inc. has announced the retirement of Caroline Dorsa from its Board of Directors and the election of Dr. Maria C. Freire as the new Chair, effective immediately after the 2026 Annual Meeting of Stockholders on June 9, 2026 [1][2]. Group 1: Leadership Transition - Caroline Dorsa has served on the Board for 16 years and expressed pride in Biogen's innovative contributions to medicine, highlighting the company's transformation under CEO Chris Viehbacher's leadership [2]. - Dr. Maria C. Freire, who joined the Board in 2021, is recognized for her extensive scientific background and will guide Biogen into its next growth phase, focusing on the company's renewed pipeline [2][3]. - Christopher A. Viehbacher, Biogen's CEO, acknowledged Dorsa's visionary leadership and expressed confidence in Freire's ability to advance the company's long-term growth strategy [2]. Group 2: Dr. Maria C. Freire's Background - Dr. Freire is the Founder and Principal of The Freire Group, with experience in biomedical innovation, drug development, and public-private partnerships [3][4]. - She previously led the Foundation for the National Institutes of Health, managing large-scale collaborations in various medical fields, including oncology and neurodegenerative diseases [4]. - Dr. Freire has a history of overseeing drug development organizations, notably advancing pretomanid for multidrug-resistant tuberculosis [5]. Group 3: Biogen's Strategic Focus - Biogen aims to leverage its deep understanding of human biology to deliver first-in-class treatments, balancing bold risks with long-term growth [9]. - The company is entering a catalyst-rich period with several important readouts expected in the next 18 months, including potential filings in lupus and nephrology [2].